Our Products

Efficacy and Patient Reported Outcomes

Discover more about ▼Olumiant® (baricitinib) efficacy and PRO data and explore the trial results from the extensive phase III clinical trial program. Hear the lead author of RA BEAM, Professor Peter Taylor present the results

Learn more
Our Products

Mechanism Of Action

To discover more about the mechanism of action behind the first JAK inhibitor approved for RA in the EU, click the link below where you can watch a video from Professor John Isaacs sharing the science behind Olumiant and the benefits of JAK inhibition.

Learn more

OUR PRODUCTS

Safety & Monitoring

Learn more

OUR PRODUCTS

HTA & Clinical Assesments

Learn more

OUR PRODUCTS

Olumiant Resources

Learn more